کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5648322 1587497 2017 26 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی امراض پوستی
پیش نمایش صفحه اول مقاله
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
چکیده انگلیسی

BackgroundSafety of biologics is important when treating patients with psoriasis.ObjectiveWe sought to determine the safety of ixekizumab in psoriasis.MethodsIntegrated safety data are presented from a 12-week induction period, a 12- to 60-week maintenance period, and from all ixekizumab-treated patients from 7 clinical trials. Exposure-adjusted incidence rates (IRs) per 100 patient-years are reported.ResultsOverall, 4209 patients received ixekizumab (total exposure: 6480 patient-years). During the induction period, the IRs of patients experiencing 1 or more treatment-emergent adverse event (AE) were 251 and 236 among ixekizumab- and etanercept-treated patients, respectively, and for serious AEs was 8.3 in both groups. During maintenance, for ixekizumab, the IRs of treatment-emergent AEs and serious AEs were 100.4 and 7.8, respectively. Among all ixekizumab-treated patients from 7 trials, the IR of Candida infections was 2.5. The IRs of treatment-emergent AEs of special interest (including serious infections, malignancies, major adverse cardiovascular events) were comparable for ixekizumab and etanercept during the induction period.LimitationsAdditional long-term data are required.ConclusionIxekizumab had an acceptable safety profile with no unexpected safety findings during ixekizumab maintenance in psoriasis.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of the American Academy of Dermatology - Volume 76, Issue 3, March 2017, Pages 432–440.e17